Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › axitinib

axitinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of axitinib

34 trials tracked of axitinib: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 36 citations.

34Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 21 Phase 1 3 Other / NA 8
  1. Phase 3 Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) Completed · 36 cited
  2. Phase 3 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas Completed · 4 cited
  3. Phase 2 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Completed
  4. Phase 2 A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) Completed
  5. Phase 2 Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer Completed
  6. Phase 2 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer Completed
Show 28 more trials
  1. Phase 2 Expansion Trial for Axitinib In Head And Neck Cancer Completed
  2. Phase 2 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed
  3. Phase 2 Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) Completed
  4. Phase 2 A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma Completed
  5. Phase 2 Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer Completed
  6. Phase 2 Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Completed
  7. Phase 2 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Completed
  8. Phase 2 Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer Completed
  9. Phase 2 Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas Completed
  10. Phase 2 Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer Completed
  11. Phase 2 A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy Completed
  12. Phase 2 Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer Completed
  13. Phase 2 A Study of Axitinib in Advanced Carcinoid Tumors Completed
  14. Phase 2 A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma Completed
  15. Phase 2 Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Completed
  16. Phase 2 Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma Completed
  17. Phase 2 SLM + Axitinib for Clear Cell RCC Completed
  18. Phase 1 Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer Completed
  19. Phase 1 A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer Completed
  20. Phase 1 A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors Completed
  21. N/A Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials Completed
  22. N/A Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) Completed
  23. N/A Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) Completed
  24. N/A Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea Completed
  25. N/A Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] Completed
  26. N/A Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. Completed
  27. N/A Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries Completed
  28. N/A To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis
Oncology
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis New combo drug stops leukemia that fought back against two drugs
This case report describes a single CML patient who relapsed with B lymphoblastic blast crisis harboring a T315I mutation and a novel e6a3 B…
A new three-drug mix stops a tough leukemia that grew stronger after two drugs failed to control it.
medRxiv Apr 24, 2026
Axitinib + Octreotide Shows PFS Benefit in Extrapancreatic NETs per Central Review (HR 0.71)
Oncology RCT
Axitinib + Octreotide Shows PFS Benefit in Extrapancreatic NETs per Central Review (HR 0.71) Can a blood vessel blocker help slow rare gut tumors? Study shows mixed results for new combination treatment
In the AXINET phase II/III trial, axitinib plus octreotide LAR significantly improved median PFS per blinded independent central review (16.…
A new blood vessel blocker combined with standard hormone shots helped rare gut tumors shrink and delayed growth longer than placebo, despit…
Mar 30, 2026